HYWEL WILLIAMS HYWEL.WILLIAMS@NOTTINGHAM.AC.UK
Professor of Dermato-Epidemiology
HYWEL WILLIAMS HYWEL.WILLIAMS@NOTTINGHAM.AC.UK
Professor of Dermato-Epidemiology
Fenella Wojnarowska
Gudula Kirtschig
James Mason
Thomas R. Godec
Enno Schmidt
J.R. Chalmers
Margaret Childs
Shernaz Walton
Karen Harman
Anna Chapman
Diane Whitham
Andrew J. Nunn
Background: Bullous pemphigoid (BP) is a blistering skin disorder with increased mortality. We tested whether a strategy of starting treatment with doxycycline conveys acceptable short-term blister control whilst conferring long-term safety advantages over starting treatment with oral corticosteroids.
Methods: Pragmatic multi-centre parallel-group randomised controlled trial of adults with BP (≥3 blisters ≥2 sites and linear basement membrane IgG/C3) plus economic evaluation. Participants were randomised to doxycycline (200 mg/day) or prednisolone (0·5 mg/kg/day). Localised adjuvant potent topical corticosteroids (<30 g/week) was permitted weeks 1-3. The non-inferiority primary effectiveness outcome was the proportion of participants with ≤3 blisters at 6 weeks. We assumed that doxycycline would be 25% less effective than corticosteroids with a 37% acceptable margin of noninferiority. The primary safety outcome was the proportion with severe, life-threatening or fatal treatment-related adverse events by 52 weeks. Analysis used a regression model adjusting for baseline disease severity, age and Karnofsky score, with missing data imputed.
Results: 132 patients were randomised to doxycycline and 121 to prednisolone from 54 UK and 7 German dermatology centres. Mean age was 77·7 years and 68.4% had moderate to severe baseline disease. For those starting doxycycline, 83/112 (74·1%) had ≤3 blisters at 6 weeks compared with 92/101 (91·1%) for prednisolone, a difference of 18·6% favouring prednisolone (upper limit of 90% CI, 26·1%, within the predefined 37% margin). Related severe, life-threatening and fatal events at 52 weeks were 18·5% for those starting doxycycline and 36·6% for prednisolone (mITT analysis), an adjusted difference of 19·0% (95% CI, 7·9%, 30·1%, p=0·001).
Conclusions: A strategy of starting BP patients on doxycycline is non-inferior to standard treatment with oral prednisolone for short-term blister control and significantly safer long-term.
Williams, H. C., Wojnarowska, F., Kirtschig, G., Mason, J., Godec, T. R., Schmidt, E., Chalmers, J., Childs, M., Walton, S., Harman, K., Chapman, A., Whitham, D., & Nunn, A. J. (in press). Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic non-inferiority randomised controlled trial. Lancet, 389(10079), https://doi.org/10.1016/S0140-6736%2817%2930560-3
Journal Article Type | Article |
---|---|
Acceptance Date | Nov 22, 2016 |
Online Publication Date | Mar 6, 2017 |
Deposit Date | Jan 3, 2017 |
Publicly Available Date | Mar 6, 2017 |
Journal | The Lancet |
Print ISSN | 0140-6736 |
Electronic ISSN | 1474-547X |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 389 |
Issue | 10079 |
DOI | https://doi.org/10.1016/S0140-6736%2817%2930560-3 |
Public URL | https://nottingham-repository.worktribe.com/output/849185 |
Publisher URL | http://www.sciencedirect.com/science/article/pii/S0140673617305603 |
Additional Information | Issued on behalf of the UK Dermatology Clinical Trials Network BLISTER Study Group |
Contract Date | Jan 3, 2017 |
1-s2.0-S0140673617305603-main.pdf
(339 Kb)
PDF
Copyright Statement
Copyright information regarding this work can be found at the following address: http://creativecommons.org/licenses/by/4.0
Validation of treatment escalation as a definition of atopic eczema flares
(2015)
Journal Article
What is a pragmatic clinical trial?
(2015)
Journal Article
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search